Novacyt Partners with Applied Microarrays in Assay Design
13 Setembro 2018 - 3:00AM
Business Wire
US partnership to facilitate the design and
optimisation for customised microarray assays
Regulatory News:
Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international
specialist in clinical diagnostics, today announces its molecular
testing division, Primerdesign Ltd. (Primerdesign), has partnered
with Applied Microarrays, Inc. (AMI), a company that specialises in
providing customised microarrays and manufacturing point-of-care
(POC) and high throughput DNA and protein arrays, to offer
comprehensive single nucleotide polymorphism (SNP) assay
development.
Primerdesign will play an integral part in designing probes for
AMI and their customers. The microarray based molecular diagnostic
tests developed under this partnership will play a crucial role in
the early diagnosis, as well as improve patient management and
outcome. Primerdesign has thirteen years’ experience in molecular
assay design and this partnership highlights the division’s pivotal
role in assay development as it grows its relationships with
leading diagnostic companies.
Working together, Primerdesign and AMI can provide a full suite
of assay development services from probe designs, through to assay
optimisation, regulatory and ultimately high volume manufacturing
of SNP microarrays for use in POC as well as laboratory-based
settings.
Alastair Malcolm, President & CEO of AMI,
commented:“Novacyt is an expert in molecular diagnostic assay
design and development and I am pleased to enter this strategic
partnership to develop customised microarray based diagnostic
tests. Through working with Primerdesign, we have been impressed
with their assay development expertise and ability to deliver a
high quality service in a timely manner. I am confident that our
partnership will help us to deliver multiplexed probe based
diagnostic and detection with better diagnosis and improved patient
outcomes.”
Graham Mullis, Group CEO of Novacyt, added:“I am
delighted that we are entering into a partnership with AMI. This
partnership significantly expands our offering and geographic reach
as we continue to expand our molecular products business.
“I am also pleased to see continued progress in our
business-to-business opportunities converting into commercial
partnerships. We are increasingly becoming the partner of choice
for molecular diagnostic companies and I look forward to updating
shareholders with further partnerships like this.”
Financial terms of the agreement have not been disclosed.
About Novacyt Group
The Novacyt Group is a rapidly growing, international
diagnostics group with a growing portfolio of cancer and infectious
disease products and services. Through its proprietary technology
platform, NOVAPrep®, and molecular platform,
genesig®, Novacyt is able to provide an extensive
range of oncology and infectious disease diagnostic products across
an extensive international distributor network. The Group has
diversified sales from diagnostic reagents used in oncology,
microbiology, haematology and serology markets, and its global
customers and partners include major corporates.
For more information please visit:
www.novacyt.com
About Applied Microarrays
AMI is a company headquartered in Tempe, AZ, which designs,
optimises and manufactures DNA and protein biosensors, and other
microarrays on glass, plastic and semiconductors. AMI operates
under ISO 9001 and ISO 13485 certification. Since acquiring GE
Healthcare’s microarray business in 2007, AMI has evolved to become
a full service provider for RUO and Dx devices.
For more information please visit:
www.appliedmicroarrays.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180912006077/en/
Novacyt SAGraham Mullis, +44 (0)1223 395472Chief
Executive OfficerorAnthony Dyer, +44 (0)1223 395472Chief Financial
OfficerorStifel Nicolaus Europe Limited (Nominated Advisor and
Joint Broker)Jonathan Senior / Fred Walsh / Ben Maddison, +44
(0)20 7610 7600orWG Partners (Joint Broker)Nigel Birks /
Chris Lee / Claes Spång, +44 (0) 203 705 9330orFTI Consulting
(International)Brett Pollard, +44 (0)20 3727
1000brett.pollard@fticonsulting.comorVictoria Foster Mitchell, +44
(0)20 3727 1000victoria.fostermitchell@fticonsulting.comorFTI
Consulting (France)Arnaud de Cheffontaines, +33 (0)147 03 69
47arnaud.decheffontaines@fticonsulting.comorAstrid Villette, +33
(0)147 03 69 51astrid.villette@fticonsulting.com
Novacyt (LSE:NCYT)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Novacyt (LSE:NCYT)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024